title: Design, synthesis and preclinical evaluation of NRC-AN-019.
abstract: Imatinib mesylate is the first tyrosine kinase inhibitor developed and approved             for the treatment of chronic myeloid leukemia (CML). In the past few years development             of resistance towards imatinib mesylate has been reported. To overcome this problem             a series of phenyl amino pyrimidine derivatives have been designed, prepared and             evaluated for anti-proliferative activity against the BCR‑ABL‑positive leukemia             cell line K562. Among these phenyl amino pyrimidine derivatives, NRC‑AN‑019 has             been found to be a promising new lead compound for the therapy of imatinib mesylate-resistant             chronic myeloid leukemia. In this communication, we describe the design, preparation             and preclinical studies of NRC‑AN‑019.
authors.affiliation: Natco Research Centre, Sanath Nagar, Hyderabad, India.
authors.forename: Kompella
authors.initials: K
authors.lastname: Amala
authors.forename: A K S
authors.initials: AK
authors.lastname: Bhujanga Rao
authors.forename: Bharathi
authors.initials: B
authors.lastname: Gorantla
authors.forename: Christopher S
authors.initials: CS
authors.lastname: Gondi
authors.forename: Jasti S
authors.initials: JS
authors.lastname: Rao
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000138:chemical synthesis* / Q000494:pharmacology*; D001549:Benzamides / Q000138:chemical synthesis* / Q000494:pharmacology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D015195:Drug Design; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D016044:Fusion Proteins, bcr-abl / Q000378:metabolism*; D006801:Humans; D000068877:Imatinib Mesylate; D007274:Injections, Intraperitoneal; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D051379:Mice; D008819:Mice, Nude; D015394:Molecular Structure; D010879:Piperazines / Q000494:pharmacology; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D011743:Pyrimidines / Q000138:chemical synthesis* / Q000494:pharmacology*; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; C583915:NRC-AN-019; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl